A Phase 1, Randomized, Open-label Study to Evaluate the Pharmacokinetics and Bioequivalence of a Levonorgestrel Vaginal Delivery System in Healthy Female Volunteers

The primary objective of this study is to evaluate the pharmacokinetics and bioequivalence of a levonorgestrel vaginal delivery system in healthy female volunteers following varying durations of administration. Assessing these parameters is essential to establish the systemic exposure profiles and ensure the consistency of drug delivery over continued use. The secondary objectives involve monitoring the physiological response to the delivery system in a healthy population.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers within the age range of 18 to 45 years. The cohort is composed of females and includes vulnerable populations.

This Phase 1, randomized, open-label, single-center study is designed to evaluate the pharmacokinetics and bioequivalence of a levonorgestrel vaginal delivery system in healthy female volunteers following different days of use. The research methodology involves a structured sequence of study visits, beginning with a screening visit to assess eligibility. Subsequent visits will facilitate the administration of the investigational product and necessary follow-up assessments to monitor physiological parameters. The study concludes with an end-of-study visit. Total participant involvement is determined by the specific dosing regimen and observation period. Early termination from the study may occur based on predefined clinical criteria or safety protocols.

Information regarding the parameters, methods, or tools for evaluating efficacy is not available in the provided source material.